Whose Teva is it Anyway?
Insights - Teva Pharmaceuticals (TEVA) announced Wednesday that its CEO, Jeremy Levin, has stepped down after a tumultuous 18-month tenure. The question now is how long will … Continue Reading
Read NowInsights
Intermune’s Esbriet Sales Surprise on Upside
Insights - Intermune (ITMN) climbed 6% on Thursday morning after the company reported increased sales of their Idiopathic Pulmonary Fibrosis drug, Esbriet (pirfenidone). Q3 sales were $19.7 … Continue Reading
Read NowKaloBios Gets Orphan Designation for Cystic Fibrosis Drug
Insights - KaloBios (KBIO) got a boost Wednesday when the U.S. FDA granted orphan drug designation to its cystic fibrosis compound (KB001-A), which is currently in phase … Continue Reading
Read Now
Here Are Some Details From Sunshine Heart’s Most Recent Presentation
Insights - On Tuesday at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, Sunshine Heart (SSH) presented updated results from the ongoing OPTIONS-HF European trial testing the … Continue Reading
Read NowGalectin and Ziopharm: Quality Progress or Creative Tail-Wagging?
Insights - A tweet from Adam Feuerstein, senior biotech correspondent for TheStreet.com, piqued our interest last week. The comment caught our eye because of the likelihood that … Continue Reading
Read NowXenoPort’s Tecfidera-Me-Too Looks Good So Far, but the Next Steps are Unclear
Insights - After the bell Monday evening XenoPort (XNPT) released results from three early studies of XP23829, the company’s novel fumaric acid ester compound and a prodrug of monomethyl … Continue Reading
Read NowThe FDA Isn’t Pleased With MiMedx
Insights - On Wednesday shortly after the lunch hour, the FDA posted publicly a letter dated August 28 that was sent to MiMedx Group (MDXG), a developer … Continue Reading
Read Now